Illei GG - Search Results

1

Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability.

Illei GG, Tackey E, Lapteva L, Lipsky PE. Illei GG, et al. Arthritis Rheum. 2004 Jun;50(6):1709-20. doi: 10.1002/art.20344. Arthritis Rheum. 2004. PMID: 15188346 Free article. Review. No abstract available.

2

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.

Illei GG, Tackey E, Lapteva L, Lipsky PE. Illei GG, et al. Arthritis Rheum. 2004 Jul;50(7):2048-65. doi: 10.1002/art.20345. Arthritis Rheum. 2004. PMID: 15248202 Free article. Review. No abstract available.

3

Biomarkers in systemic lupus erythematosus.

Illei GG, Lipsky PE. Illei GG, et al. Curr Rheumatol Rep. 2004 Oct;6(5):382-90. doi: 10.1007/s11926-004-0013-4. Curr Rheumatol Rep. 2004. PMID: 15355751 Review.

4

Abnormal differentiation of memory T cells in systemic lupus erythematosus.

Fritsch RD, Shen X, Illei GG, Yarboro CH, Prussin C, Hathcock KS, Hodes RJ, Lipsky PE. Fritsch RD, et al. Among authors: illei gg. Arthritis Rheum. 2006 Jul;54(7):2184-97. doi: 10.1002/art.21943. Arthritis Rheum. 2006. PMID: 16802356 Free article.

5

Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus.

Lapteva L, Nowak M, Yarboro CH, Takada K, Roebuck-Spencer T, Weickert T, Bleiberg J, Rosenstein D, Pao M, Patronas N, Steele S, Manzano M, van der Veen JW, Lipsky PE, Marenco S, Wesley R, Volpe B, Diamond B, Illei GG. Lapteva L, et al. Among authors: illei gg. Arthritis Rheum. 2006 Aug;54(8):2505-14. doi: 10.1002/art.22031. Arthritis Rheum. 2006. PMID: 16868971 Free article.

6

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Illei GG, et al. Arthritis Rheum. 2010 Feb;62(2):542-52. doi: 10.1002/art.27221. Arthritis Rheum. 2010. PMID: 20112381 Free PMC article. Clinical Trial.

7

Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Tackey E, Lipsky PE, Illei GG. Tackey E, et al. Among authors: illei gg. Lupus. 2004;13(5):339-43. doi: 10.1191/0961203304lu1023oa. Lupus. 2004. PMID: 15230289 Free PMC article. Review.

8

Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.

Valencia X, Yarboro C, Illei G, Lipsky PE. Valencia X, et al. J Immunol. 2007 Feb 15;178(4):2579-88. doi: 10.4049/jimmunol.178.4.2579. J Immunol. 2007. PMID: 17277168 Clinical Trial.

9

Identification and characterization of circulating human transitional B cells.

Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Sims GP, et al. Among authors: illei gg. Blood. 2005 Jun 1;105(11):4390-8. doi: 10.1182/blood-2004-11-4284. Epub 2005 Feb 8. Blood. 2005. PMID: 15701725 Free PMC article.

10

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus.

Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Shirota Y, et al. Among authors: illei gg. Ann Rheum Dis. 2013 Jan;72(1):118-28. doi: 10.1136/annrheumdis-2012-201310. Epub 2012 Aug 2. Ann Rheum Dis. 2013. PMID: 22858586 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters